U.S. markets closed

Sucampo gets UK approval for Amitiza

Sucampo Pharmaceuticals announced the approval from the Medicines and Healthcare products Regulatory Agency for AMITIZA® (lubiprostone) 24 mcg twice daily for the treatment of chronic idiopathic constipation and associated symptoms in adults, when response to diet and other non-pharmacological measures (e.g., educational measures, physical activity) are inappropriate.